產(chǎn)品名稱 |
NCEB-1 |
商品貨號(hào) |
B244813 |
Organism |
Homo sapiens; Mus musculus, human; mouse |
Tissue |
peripheral blood |
Cell Type |
lymphoblast; immortalized with Epstein-Barr virus (EBV); Epstein-Barr virus (EBV) transforme |
Product Format |
frozen |
Morphology |
lymphoblast |
Culture Properties |
suspension |
Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease |
lymphoma |
Age |
57 year old ( human) |
Applications |
ATCC cautions scientist on the use of the NCEB-1 cell line as an in vitro model for the study of Mantle Cell Lymphoma. Cytogenetic analysis of the cell line demonstrated two clones with variations: a hypodiploid clone, with a complex karyotype including a t(11;14)(q13;q32) similar to the original tumor cells, and a near tetraploid clone with the same markers. This finding at ATCC is based on karyotyping analysis (G-banding). NCEB-1 was established by Epstein-Barr virus (EBV) transformation of peripheral blood mononuclear cells from a patient with centroblastic-centrocytic diffuse lymphoma expressing IgM lambda. |
Storage Conditions |
Liquid nitrogen vapor phase |
Karyotype |
This is a near tetraploid human/mouse hybrid cell line with a modal chromosome number of 94 and a low polyploidy rate. Most of the derivative chromosomes described in the original cell line, including the t(11;14)(q13;q32) marker are still present. All of the examined cells of this cell line contain several intact mouse chromosomes. |
Images |
|
Derivation |
NCEB-1 was established by Epstein-Barr virus (EBV) transformation of peripheral blood mononuclear cells from a patient with centroblastic-centrocytic diffuse lymphoma expressing IgM lambda. Cytogenetic analysis of the cell line demonstrated two clones with variations: a hypodiploid clone, with a complex karyotype including a t(11;14)(q13;q32) similar to the original tumor cells, and a near tetraploid clone with the same markers. The cell line was not tumorigenic when tested in an in vitro assay using immunosuppressed mice. [PubMed: 2848599]. It was reported in 2006 that surprisingly, NCEB-1 carried several stable mouse chromosomes and showed expression of both human and murine bcl-2 protein. [PubMed: 16448697]. ATCC cautions scientist on the use of the NCEB-1 cell line as an in vitro model for the study of Mantle Cell Lymphoma. Published data from researchers and testing performed during the ATCC accessioning process have confirmed that this cell line is a human-mouse hybrid. This finding at ATCC is based on karyotyping analysis (G-banding). |
Clinical Data |
NCEB-1 was established by Epstein-Barr virus (EBV) transformation of peripheral blood mononuclear cells from a patient with centroblastic-centrocytic diffuse lymphoma expressing IgM lambda. |
Antigen Expression |
CD3-, CD5+, CD10-, CD19+, CD20+, CD23+, FMC7- (verified at ATCC) |
Genes Expressed |
CD3-, CD5+, CD10-, CD19+, CD20+, CD23+, FMC7- (verified at ATCC) |
Comments |
NCEB-1 was established by Epstein-Barr virus (EBV) transformation of peripheral blood mononuclear cells from a patient with centroblastic-centrocytic diffuse lymphoma expressing IgM lambda. Cytogenetic analysis of the cell line demonstrated two clones with variations: a hypodiploid clone, with a complex karyotype including a t(11;14)(q13;q32) similar to the original tumor cells, and a near tetraploid clone with the same markers. The cell line was not tumorigenic when tested in an in vitro assay using immunosuppressed mice. [PubMed: 2848599]. It was reported in 2006 that surprisingly, NCEB-1 carried several stable mouse chromosomes and showed expression of both human and murine bcl-2 protein. [PubMed: 16448697]. ATCC cautions scientist on the use of the NCEB-1 cell line as an in vitro model for the study of Mantle Cell Lymphoma. Published data from researchers and testing performed during the ATCC accessioning process have confirmed that this cell line is a human-mouse hybrid. This finding at ATCC is based on karyotyping analysis (G-banding). |
Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
|
Subculturing |
Protocol: Cultures can be maintained by the addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(4) to 2 X 10(4) viable cells/ml. Do not allow the cell concentration to exceed 1.2 X 10(6) cells/ml. Medium renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
Cryopreservation |
Freeze medium: fetal bovine serum, 60%; RPMI-1640 Medium, 30%; DMSO, 10% strong>Storage temperature: liquid nitrogen vapor phase |
STR Profile |
Amelogenin: X CSF1PO: 12,13 D13S317: 12 D16S539: 9,10 D5S818: 9,11 D7S820: 10,11 THO1: 6,9.3 TPOX: 11 vWA: 14,18 |
Population Doubling Time |
about 19 hours |
Name of Depositor |
E. Campo |
Year of Origin |
1987 |
References |
Salaverria I, et al. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 91: 11-16, 2006. PubMed: 16434365
Camps, J., et al. Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res. 30(8):923-934 (2006). PubMed: 16448697
Saltman, D.L., et al. Characterization of a new non-Hodgkin's lymphoma cell line (NCEB-1) with a chromosomal (11:14) translocation [t(11:14)(q13;q32)]. Blood.;72(6):2026-2030 (1988). PubMed: 2848599
|